Neuropeptid S

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
edit
Neuropeptid S
Identifikatori
SimbolNPS
Vanjski IDOMIM:609513MGI:3642232HomoloGene:106066GeneCards:NPS Gene
Ortolozi
VrstaČovekMiš
Entrez594857100043254
EnsemblENSG00000214285ENSMUSG00000073804
UniProtP0C0P6P0C0P8
RefSeq (mRNA)NM_001030013XM_001479305
RefSeq (protein)NP_001025184NP_001157083
Lokacija (UCSC)Chr 10:
129.24 - 129.24 Mb		Chr 7:
142.46 - 142.46 Mb
PubMedpretraga[1][2]

Neuropeptid S (NPS)jeneuropeptidnađen umozguljudi i sisara. Njega uglavnom proizvode neuroniamigdale,mada NPS-responsivni neuroni pružaju projekcije u mnoge druge oblasti mozga.[1][2][3]NPS se specifično vezuje zaNPSRG protein-spregnuti receptor.[4][5]Ispitivanja na životinjama su pokazala da NPS umanjujeanksioznostiapetit,indukujebudnostihiperaktivnost,što obuhvata hiper-seksualnost, i ima znatnu ulogu u iskorenjivanju uslovljenog straha.[6][7][8][9][10][11][12]Takođe je bilo pokazano da znatno uvećavadopaminskuaktivnost umezolimbnom putu.[12]

Sintetički ligandi

[uredi|uredi kod]

Ne-peptidni antagonist NPS receptora,SHA-68,blokira NPS dejstvo kod životinja i proizvodi anksiogene efekte.[13]Nekoliko peptidnih agonista u antagonista izvedenih iz NPS je takođe poznato.[14][15][16][17][18]

Peptidna sekvenca

[uredi|uredi kod]

Sekvence neuropeptida S u nekoliko životinjskih vrsta:

vrsta sekvenca molekulska težina
čovek SFRNGVGTGMKKTSFQRAKS 2187.5
pacov SFRNGVGSGVKKTSFRRAKQ 2210.5
miš SFRNGVGSGAKKTSFRRAKQ 2182.5
pas, šimpanza SFRNGVGTGMKKTSFRRAKS 2215.6
kokoška SFRNGVGSGIKKTSFRRAKS 2183.5
konsenzus SFRNGVGxGXKKTSFxRAKx N/A

Literatura

[uredi|uredi kod]
  1. ↑Xu YL, Gall CM, Jackson VR, Civelli O, Reinscheid RK (January 2007). „Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain”.The Journal of Comparative Neurology500(1): 84–102.DOI:10.1002/cne.21159.PMID17099900.
  2. ↑Jüngling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, Clark SD, Okamura N, Duangdao DM, Xu YL, Reinscheid RK, Pape HC (July 2008).„Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala”.Neuron59(2): 298–310.DOI:10.1016/j.neuron.2008.07.002.PMC2610688.PMID18667157.
  3. ↑Meis S, Bergado-Acosta JR, Yanagawa Y, Obata K, Stork O, Munsch T (2008). Grothe, Benedikt. ur.„Identification of a neuropeptide S responsive circuitry shaping amygdala activity via the endopiriform nucleus”.PLoS ONE3(7): e2695.DOI:10.1371/journal.pone.0002695.PMC2442874.PMID18628994.
  4. ↑Reinscheid RK, Xu YL (December 2005). „Neuropeptide S and its receptor: a newly deorphanized G protein-coupled receptor system”.The Neuroscientist: a Review Journal Bringing Neurobiology, Neurology and Psychiatry11(6): 532–8.DOI:10.1177/1073858405276405.PMID16282594.
  5. ↑Reinscheid RK (2008). „Neuropeptide S: anatomy, pharmacology, genetics and physiological functions”.Results and Problems in Cell Differentiation46:145–58.DOI:10.1007/400_2007_051.PMID18204825.
  6. ↑Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O (August 2004). „Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects”.Neuron43(4): 487–97.DOI:10.1016/j.neuron.2004.08.005.PMID15312648.
  7. ↑Reinscheid RK, Xu YL (November 2005). „Neuropeptide S as a novel arousal promoting peptide transmitter”.The FEBS Journal272(22): 5689–93.DOI:10.1111/j.1742-4658.2005.04982.x.PMID16279934.
  8. ↑Okamura N, Reinscheid RK (August 2007). „Neuropeptide S: a novel modulator of stress and arousal”.Stress (Amsterdam, Netherlands)10(3): 221–6.DOI:10.1080/10253890701248673.PMID17613937.
  9. ↑Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, Malberg JE, Beyer CE, Schechter LE, Rosenzweig-Lipson S, Ring RH (May 2008).„Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders”.Psychopharmacology197(4): 601–11.DOI:10.1007/s00213-008-1080-4.PMID18311561.
  10. ↑Rizzi A, Vergura R, Marzola G, Ruzza C, Guerrini R, Salvadori S, Regoli D, Calo G (May 2008).„Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice”.British Journal of Pharmacology154(2): 471–9.DOI:10.1038/bjp.2008.96.PMC2442439.PMID18376418.
  11. ↑Vitale G, Filaferro M, Ruggieri V, Pennella S, Frigeri C, Rizzi A, Guerrini R, Calò G (December 2008). „Anxiolytic-like effect of neuropeptide S in the rat defensive burying”.Peptides29(12): 2286–91.DOI:10.1016/j.peptides.2008.08.014.PMID18793688.
  12. ↑12,012,1Mochizuki T, Kim J, Sasaki K (February 2010).„Microinjection of neuropeptide S into the rat ventral tegmental area induces hyperactivity and increases extracellular levels of dopamine metabolites in the nucleus accumbens shell”.Peptides31(5): 926–31.DOI:10.1016/j.peptides.2010.02.006.PMID20156501.
  13. ↑Okamura N, Habay SA, Zeng J, Chamberlin AR, Reinscheid RK (June 2008).„Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-apyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor” ].The Journal of Pharmacology and Experimental Therapeutics325(3): 893–901.DOI:10.1124/jpet.107.135103.PMC2583099.PMID18337476.
  14. ↑Roth AL, Marzola E, Rizzi A, Arduin M, Trapella C, Corti C, Vergura R, Martinelli P, Salvadori S, Regoli D, Corsi M, Cavanni P, Caló G, Guerrini R (July 2006). „Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation”.The Journal of Biological Chemistry281(30): 20809–16.DOI:10.1074/jbc.M601846200.PMID16720571.
  15. ↑Camarda V, Trapella C, Calo G, Guerrini R, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S (February 2008). „Synthesis and biological activity of human neuropeptide S analogues modified in position 2”.Journal of Medicinal Chemistry51(3): 655–8.DOI:10.1021/jm701204n.PMID18181564.
  16. ↑Camarda V, Trapella C, Calo' G, Guerrini R, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S (October 2008). „Structure-activity study at positions 3 and 4 of human neuropeptide S”.Bioorganic & Medicinal Chemistry16(19): 8841–5.DOI:10.1016/j.bmc.2008.08.073.PMID18793857.
  17. ↑Guerrini R, Camarda V, Trapella C, Calò G, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S (January 2009).„Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists”.Journal of Medicinal Chemistry52(2): 524–9.DOI:10.1021/jm8012294.PMC2653091.PMID19113861.
  18. ↑Camarda V, Rizzi A, Ruzza C, Zucchini S, Marzola G, Marzola E, Guerrini R, Salvadori S, Reinscheid RK, Regoli D, Calò G (February 2009).„In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5neuropeptide S” ].The Journal of Pharmacology and Experimental Therapeutics328(2): 549–55.DOI:10.1124/jpet.108.143867.PMC2630366.PMID18971372.
Izvor:https://sh.wikipedia.org/w/index.php?title=Neuropeptid_S&oldid=41418231